ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (696)	9/13/1999 1:00:00 PM
From: Jim Haynes	Read Replies (2) of 4474

Mike, CFO Jay La Marche returned my call this morning. I didn't have a chance to ask the questions you posed, as I was runnning late for a tennis encounter. He did explain the redemption feature of the class C preferred, which I suppose most of you already understood. The common issued on conversion may be redeemed at the conversion price if less than $1.95. I neglected to ask how long the company has to exercise the redemption after a demand for conversion. La Marche said the company has no existing arrangement with any outside source to finance such a redemption. I asked some questions about a possible acquisition of the company. He, of course, parried my questions. Nevertheless, I am convinced, if the science is good, there are bigger companies which would pay a premium of the market cap to buy Ariad, so there must have been some discussions. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next